



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

7 Sep 2020 (#40)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Important Notices

- **NOT-CA-20-098: Notice of Intent to Publish a Funding Opportunity Announcement for Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)** The National Cancer Institute (NCI) intends to promote a reissuance of an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. The FOA is expected to be published in October 2020 with an expected application due date in December 2020. **Budget:** Up to \$3,000,000 in both fiscal year (FY) 2021 and 2022. Approximately 4-6 R01 awards each fiscal year of \$500,000 Direct Costs per year. The link to the previous RFA can be accessed here: <https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-18-013.html>
- **NOT-AG-20-041: Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care.** This NOSI encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies. Topics of interest among Institutes and Centers (ICs) participating in this NOSI are summarized in the notice. Applicants are encouraged to contact the Scientific/Research contacts listed below to ensure that proposed aims are consistent with the mission(s) of the intended IC(s).
- **NOT-HD-20-021: Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract.** The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.

- **[NOT-HD-20-026: Notice of Special Interest: Optimizing Precision Treatment of Gynaecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions \(Clinical Trial Optional\)](#)**. The National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators to apply for funding to optimize treatments of comorbid conditions in adolescents and reproductive age women with a diagnosis of Polycystic Ovary Syndrome (PCOS). The goals of this initiative are to stimulate interdisciplinary scientific collaboration between gynaecologists/reproductive endocrinologists/obstetricians and subspecialists in diverse medical fields, including cardiologists, endocrinologists, gastroenterologists, psychiatrists, mental health professionals, pulmonologists, among others, to: 1) advance individualized treatments consistent with gynaecologic, reproductive and obstetrical needs and desires; 2) promote translational and clinical research to increase knowledge and understanding of interaction of various therapies on gynaecologic, reproductive and obstetric outcomes; and 3) discover and develop novel safe and more effective therapies for adolescents and women with PCOS with underlying comorbid conditions. Ultimately, this research would advance precision therapeutics for adolescents and adults with PCOS who have concomitant medical conditions.

Upcoming Deadlines

- **[Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#)**:
Research Training Program due date: 24 November 2020
Ethical, Legal, and Social Implications Research due date: 1 December 2020
Open Data Science Platform and Coordinating Center due date: 3 December 2020
Research Hubs non-AIDS application due date: 8 December 2020
Research Hubs AIDS application due date: 8 February 2021
- **[Mobile Health: Technology and Outcomes in LMICs](#)** 24 September 2020; AIDS deadline 3 December 2020
- **[Emerging Global Leader Award](#)** 4 November 2020
- **[Global Brain Disorders Research](#)** 6 November 2020
- **[Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#)** 12 November 2020
- **[Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#)** D43 13 November 2020
- **[Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#)** 18 November 2020

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **[PA-20-185](#)** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **[PA-20-184](#)** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **[PA-20-183](#)** Research Project Grant (Parent R01 Clinical Trial Required)
- **[PA-20-200](#)** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **[PA-20-195](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **[PA-20-194](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **[PA-20-196](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunities

1. HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)		
Letter of Intent: 30 days prior to the application due date	Hyperlink: PAR-21-024	Type: P01
Application Due Date: March 15, 2021; March 15, 2022; March 15, 2023. Apply by 5:00 PM local time of applicant organization.		
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.		
Budget: NIH intends to fund an estimate of 1-2 awards, corresponding to a total of \$5M, for fiscal year 2022. Future year amounts will depend on annual appropriations. Application budgets are limited to \$2.5M per year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.		

2. Genomic Data Analysis Network: Genomic Data Center (U24 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-053](#)

Type: U24

Application Due Date: November 12, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is designed to support genomic programs managed by the Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. These data could, in the future, be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. It is not the intent of this FOA to fund follow-up translational and functional studies, but rather to enable the cancer research community to develop a new generation of studies that will leverage the genomic findings from NCI programs for the benefit of cancer patients. NCI project data, both ongoing and completed, will provide a unique reference resource on cancer-specific genomic aberrations for the cancer research community at large.

Budget: The NCI intends to support up to 10 GDAC awards for a total of \$10 million (total costs). Future year amounts will depend on annual appropriations. Application budgets are limited to \$300,000/year in direct costs but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Toward Elucidating Mechanisms Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-20-023](#)

Type: R01

Application Due Date: March 3, 2021 and November 17, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and physiology, pathophysiology, pathobiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will provide comprehensive mechanistic analyses of the processes leading to the establishment and persistence of latent HIV reservoirs in anatomical sites relevant to the mission of the NIDDK, with the purpose of advancing progress toward developing a cure.

Budget: NIDDK intends to commit \$2,000,000 in FY 2022 to fund 3-4 awards. Application budgets are limited to \$500,000 direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. National Eye Institute (NEI) Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-EY-20-001](#)

Type: U24

Application Due Date: January 15, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Applicants are expected to propose research projects that use novel model systems in a cell-replacement therapy study. Non-human primate or human retinal organoid models are expected. Other model systems are acceptable if they use human cells as the replacement therapy. An important aspect of this FOA is that the research team is expected to treat the loss of vision associated with the experimental model using an approach that involves regenerating PRCs and/or RGCs and their connections. The choice of cells for therapy might include adult stem cells, precursors, stem cell derived progenitor cells, or employ methods for converting endogenous cells such as glia into PRCs or RGCs. It is also expected that quantitative measures will be used to evaluate survival and integration of the regenerated cells using electrophysiology, functional imaging, behavioral measures or any other appropriate technology that would demonstrate circuit integration and restoration of visual function.

Budget: The NEI intends to commit \$5-6 million in FY 2020 to fund 3-4 awards. Applicants may request up to \$1 million per year direct costs (exclusive of consortium facilities and administrative costs). The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105

